Ligand Pharmaceuticals Incorporated LGND

301.52 2.48 0.83% as of 25 Sep
Market cap
$6.1B
P/E
30.1×
Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
P/E ratio
0.00 144.13 12.54 2.13 0.00 27.85 0.00 23.79 0.00 30.01
P/S ratio
12.22 12.89 7.12 10.27 6.14 6.63 5.68 9.53 11.73 13.64
P/FCF ratio
32.34 19.20 9.42 0.00 20.56 23.24 9.96 0.00 21.84 60.02
P/Operating CF
71.13 58.09 54.99 (168.39) 1,869.86 57.97 20.83 155.09 68.83 79.63
P/B ratio
3.90 4.55 3.19 1.61 1.42 1.95 1.86 1.78 2.36 3.59
EV/Sales
13.15 13.19 6.58 6.70 6.38 6.56 5.04 8.27 10.17 12.48
EV/EBITDA
21.57 20.37 7.62 0.93 11.59 9.23 17.87 22.93 144.18 47.07
EV/FCF
34.80 19.64 8.70 (22.97) 21.36 22.98 8.84 (281.92) 18.94 54.93
Current Ratio
0.72 0.99 10.58 66.09 5.00 11.15 2.67 14.15 8.93 22.23
Net Debt/EBITDA
1.53 0.46 (0.63) (0.49) 0.43 (0.11) (2.26) (3.59) (22.58) (4.36)
Debt/Equity
0.71 0.61 1.13 0.83 0.63 0.39 0.15 0.00 0.00 0.44
ROE
(0.57%) 3.39% 29.84% 94.76% (0.40%) 7.47% (4.70%) 8.03% (0.53%) 13.47%
ROA
(0.30%) 1.97% 14.84% 45.67% (0.21%) 4.30% (3.24%) 6.73% (0.47%) 9.95%
ROIC
6.20% 9.64% 24.17% 149.54% 3.13% 8.10% 0.40% 1.41% (2.50%) 3.62%
Return on Tangible Assets
2.63% 530.91% 18.06% 56.50% (0.72%) 13.10% (18.82%) 22.08% (1.30%) 15.66%
Average Days of Receivables
49.24 66.21 81.28 126.69 131.81 138.49 65.17 109.27 92.70 83.12
Earnings Yield
(0.09%) 0.69% 7.97% 47.05% (0.23%) 3.59% (3.00%) 4.20% (0.05%) 3.33%
Free Cash Flow Yield
3.09% 5.21% 10.61% (2.84%) 4.86% 4.30% 10.04% (0.31%) 4.58% 1.67%
Free Cash Flow per Share
1.98 4.44 8.66 (1.68) 3.18 4.24 7.12 (0.22) 4.64 2.50
Book value per Share
16.38 19.01 26.51 40.39 43.84 49.38 35.42 40.52 45.40 52.60
Free Cash Flow
41.19 93.47 183.17 (31.89) 51.49 70.53 120.02 (3.85) 84.84 48.31
EV/EBIT
32.66 27.33 10.10 1.00 27.82 15.25 325.52 90.98 0.00 81.61
Other line items

Show all line items

Columns are period end dates